Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, discusses the 5-year overall survival (OS) results of CPX-351 (Vyxeos) versus 7+3 (cytarabine and anthracycline) in patients with newly diagnosed high-risk or secondary acute myeloid leukemia (AML).
Eighteen percent of patients who received CPX-351 were alive at 5 years compared with 8% who received 7+3. Cortes says there was clearly still a benefit long term and although the investigators would like to see higher OS rates, the doubling of survival in the CPX-351 arm was important.
The subgroup analyses showed that the benefits of CPX-351 were maintained across age groups on this phase 3 trial. The 3-year survival in the patients 60 to 69 years old, was 23% versus 14% for CPX-351 and 7+3, respectively. For patients 70 to 75 years old, there was an 18% 3-year OS rate for CPX-351 compared with 0% with 7+3. At 5 years, the OS was 20% in the younger population receiving CPX-351 and 12% for those receiving 7+3. For the older population, the survival rate at 5 years was 16% versus 0%, respectively. The benefit with CPX-351 was applicable to both age groups, according to Cortes.
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More